141 related articles for article (PubMed ID: 32890137)
1. Considerations for Child Cancer Survivors and Immunocompromised Children to Prevent Secondary HPV-associated Cancers.
Imburgia TM; Shew ML; Gravitt PE; Katzenellenbogen RA
Transplantation; 2021 Apr; 105(4):736-742. PubMed ID: 32890137
[TBL] [Abstract][Full Text] [Related]
2. HPV vaccination of immunocompromised hosts.
Garland SM; Brotherton JML; Moscicki AB; Kaufmann AM; Stanley M; Bhatla N; Sankaranarayanan R; de Sanjosé S; Palefsky JM;
Papillomavirus Res; 2017 Dec; 4():35-38. PubMed ID: 29179867
[TBL] [Abstract][Full Text] [Related]
3. Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations.
Zottnick S; Voß AL; Riemer AB
Front Immunol; 2020; 11():1750. PubMed ID: 32922389
[TBL] [Abstract][Full Text] [Related]
4. Implications for human papillomavirus in penile cancer.
Flaherty A; Kim T; Giuliano A; Magliocco A; Hakky TS; Pagliaro LC; Spiess PE
Urol Oncol; 2014 Jan; 32(1):53.e1-8. PubMed ID: 24239463
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccines.
Satyaprakash A; Creed R; Ravanfar P; Mendoza N
Dermatol Ther; 2009; 22(2):150-7. PubMed ID: 19335726
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccination uptake among childhood cancer survivors in Western New York.
Garcia M; McGillicuddy C; Rodriguez EM; Attwood K; Schweitzer J; Coley S; Rokitka D; Schlecht NF
Pediatr Blood Cancer; 2022 Nov; 69(11):e29962. PubMed ID: 36094384
[TBL] [Abstract][Full Text] [Related]
7. No Vacillation on HPV Vaccination.
Sipp D; Frazer IH; Rasko JEJ
Cell; 2018 Mar; 172(6):1163-1167. PubMed ID: 29522737
[TBL] [Abstract][Full Text] [Related]
8. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
Front Immunol; 2020; 11():188. PubMed ID: 32133000
[TBL] [Abstract][Full Text] [Related]
9. Postpartum HPV Vaccination Rate and Differences in Background Characteristics Between HPV Vaccinated and Unvaccinated Postpartum Women: Strict Monitoring and Follow-Up of Postpartum HPV Vaccination Program.
Lee CY; Tseng CJ; Chang CC; Lee MC; Yang SF
Front Immunol; 2021; 12():626582. PubMed ID: 34054800
[TBL] [Abstract][Full Text] [Related]
10. An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy.
Yousefi Z; Aria H; Ghaedrahmati F; Bakhtiari T; Azizi M; Bastan R; Hosseini R; Eskandari N
Front Immunol; 2021; 12():805695. PubMed ID: 35154080
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void Urine.
Pattyn J; Van Keer S; Téblick L; Van Damme P; Vorsters A
Front Immunol; 2020; 11():1657. PubMed ID: 32849573
[TBL] [Abstract][Full Text] [Related]
12. Suboptimal uptake of human papillomavirus (HPV) vaccine in survivors of childhood and adolescent and young adult (AYA) cancer.
Castellino SM; Allen KE; Pleasant K; Keyes G; Poehling KA; Tooze JA
J Cancer Surviv; 2019 Oct; 13(5):730-738. PubMed ID: 31342304
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus vaccine: widening the scope for cancer prevention.
No JH; Kim MK; Jeon YT; Kim YB; Song YS
Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study.
Grein IHR; Pinto NBF; Groot N; Martins CB; Lobo A; Aikawa NE; Barbosa C; Terreri MT; da Fraga ACM; de Oliveira SKF; Sztajnbok F; Paim Marques LB; Islabão AG; Appenzeller S; Bica B; de Oliveira Sato J; Magalhães CS; Ferriani V; Pasmans H; Schepp R; van der Klis F; de Roock S; Wulffraat N; Pileggi GS
Pediatr Rheumatol Online J; 2020 Nov; 18(1):87. PubMed ID: 33176806
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus and genital cancer.
Rapose A
Indian J Dermatol Venereol Leprol; 2009; 75(3):236-43; quiz 243-4. PubMed ID: 19439875
[TBL] [Abstract][Full Text] [Related]
16. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
MacIntyre CR; Shaw P; Mackie FE; Boros C; Marshall H; Barnes M; Seale H; Kennedy SE; Moa A; Hayen A; Chughtai AA; O'Loughlin EV; Stormon M
Vaccine; 2016 Aug; 34(36):4343-50. PubMed ID: 27406936
[TBL] [Abstract][Full Text] [Related]
18. The known unknowns of HPV natural history.
Gravitt PE
J Clin Invest; 2011 Dec; 121(12):4593-9. PubMed ID: 22133884
[TBL] [Abstract][Full Text] [Related]
19. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
20. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
